UltiMaker and Bioactivx Partnered on 3D Printed Skin
Healthcare providers may soon access on-demand artificial skin production to reduce patient wait times.
Updated on Sept. 19, 2026 in Healthcare
Live Poll
Do you believe on-demand medical manufacturing at clinics will improve patient care?
UltiMaker and Bioactivx signed a memorandum of understanding to advance decentralized 3D printing of Bioactiv Matrix, an animal-free artificial skin substitute. The collaboration follows Bioactivx receiving Health Sciences Authority approval for the product in Singapore.
Why it matters
By shifting manufacturing to treatment sites, the partnership aims to minimize the interval between injury and clinical application. The initiative represents a broader push to decentralize medical device supply chains for faster patient care.
Bioactivx currently holds a level 4 World Health Organization medical device maturity rating. The company operates under ISO 13485 certification for end-use medical manufacturing.
The players
UltiMaker
A developer and manufacturer of desktop 3D printing hardware and software solutions.
Bioactivx
A Singapore-based medical technology firm focused on synthetic skin substitutes and cleanroom manufacturing.
Health Sciences Authority
The Singaporean regulatory agency responsible for the safety and efficacy of medical devices.
The details
Bioactivx produces its synthetic skin using proprietary active-ingredient filaments on UltiMaker 3D printing hardware. All production takes place within a certified cleanroom facility to meet medical standards. The companies are currently refining the printing configuration to ensure consistent quality for decentralized deployment.
Timeline
September 19, 2026: The memorandum of understanding was announced alongside news of HSA approval.
2025: Cutiss reported positive interim clinical trial results.
Market Landscape
The move reflects a shift toward point-of-care manufacturing within the medical device sector, governed by the ISO 13485 quality management standard. This strategy seeks to decouple critical supply chains from centralized facilities by utilizing certified hardware near the treatment site.
Operators in the medical supply chain should monitor the certification requirements for decentralized manufacturing sites as clinical trials progress. Future procurement strategies may need to account for localized printing capabilities rather than traditional inventory-based models.
The takeaway
Decentralized 3D printing is emerging as a practical solution for time-sensitive medical products. Management should track upcoming regulatory approvals in the U.S. and EU to determine if localized production models offer a viable alternative to existing logistics.
Further reading
For more on the latest trends in medical technology, visit the Healthcare section.
Source note: This article includes information reported by 3D Printing Industry.
Live Poll
Do you believe on-demand medical manufacturing at clinics will improve patient care?
